Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Complications

NCT06553027 is registered in ClinicalTrials.gov with Cerevance as lead sponsor.

NCT NCT06553027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06553027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Complications
Lead sponsor
Cerevance
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 20, 2024
Completion date
August 31, 2026
Enrollment
330 (estimated)
Sites
94

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease